Vietnam's electronic-record deadline creates infrastructure for clinical AI. It does not create clinical intelligence by itself.
Circular 13/2025/TT-BYT required licensed hospitals to implement electronic medical records by 30 September 2025. Other facilities providing inpatient, day, and outpatient treatment must complete implementation by 31 December 2026. In April 2026, the Ministry of Health reported that more than 75% of hospitals had announced an implementation. The same update said that some facilities had not fully replaced paper in daily work.
That is a more useful starting point than saying Southeast Asia is simply "going paperless." A hospital can meet an implementation milestone while still carrying incomplete historical records, uneven data quality, and workflows that are hard for another system to read.
The mandate specifies a record system, not an AI system
Circular 13 is concrete about the electronic-record base. It requires IT infrastructure, clinical applications, backup storage, information security, and data that can be retrieved for treatment, inspection, research, and management. It does not require a clinical decision-support system. It does not say that data will be normalized across vendors, or that a model can safely interpret every field.
An electronic record and clinical decision support therefore solve different problems. The record stores and retrieves the chart. Decision support has to select the relevant patient context, compare it with appropriate clinical knowledge, expose missing information, and reach the doctor while the decision can still change.
The distinction matters because a chatbot beside an EMR can still leave the hard work with the clinician. If the doctor has to copy the case, check every source, and reconcile the answer with local medicines or reimbursement rules, the interface has moved but the workload has not.
Southeast Asia is not an empty market
UpToDate supports search in 16 languages, including Vietnamese and Bahasa Indonesian. Its 2025 APAC announcement says the enterprise edition was already used at more than 200 hospitals across Australia, New Zealand, Singapore, Taiwan, and Hong Kong. Those facts show multilingual access and regional deployment. They do not, on their own, establish coverage of a Vietnamese hospital's formulary, insurance rules, or internal workflow.
MIMS Integrated is stronger evidence that the region already has localized clinical decision support. Its public page lists country-specific medicine modules for Vietnam, Thailand, Malaysia, Indonesia, Singapore, and the Philippines, along with drug-interaction, allergy, duplicate-therapy, dose, pregnancy, and lactation checks. It also lists Vietnam Ministry of Health contraindications among its interoperability mappings.
The unfinished work is in the connections: patient context from the hospital record, local evidence and medication data, prescription checks, and a result the doctor can inspect without rebuilding the case by hand.
What Meddies can claim today
The Meddies repository contains FHIR tool implementations designed to retrieve observations, medications, diagnoses, encounters, and longitudinal patient data from OpenEMR. Those tools are not registered in the live chat toolset. Knowledge search, drug interaction, and deterministic safety review are registered there.
The repository implementations establish what has been built, while the live toolset establishes what chat can currently call. Neither proves compatibility with every hospital EMR, complete coverage of Vietnamese formularies or insurance codes, or better clinical decisions and patient outcomes.
The supported claim is narrower. Meddies is being built from the workflow of a Vietnamese hospital outward: read the patient context the system can provide, gather relevant evidence, run explicit safety checks, and keep the doctor responsible for the decision. Each part still needs testing against local data, local systems, and real clinical work.
Southeast Asia does not need a translated claim that an AI product is "regional." It needs evidence that the product works with the region's records, medicines, rules, and clinical constraints. Only deployment can supply that evidence.